Key Takeaways Weed stocks dropped Monday afternoon, reversing early gains on hopes President Trump could soon issue an executive order reclassifying marijuana. An expected reclassification from a Schedule I to a Schedule III drug would help companies in the sector reduce their taxes and relax banking restrictions. Weed stocks aren't flying so high anymore. Shares of Tilray Brands (TLRY) dropped nearly 5%, Canopy Growth (CGC) slipped 3%, and other cannabis stocks also lost ground in recent trading, reve ...

Group 1: Market Reaction and Regulatory Changes - Canadian cannabis stocks, including Tilray (TLRY), surged following reports that President Donald Trump could sign an executive order reclassifying marijuana from a Schedule I drug to Schedule III, which would allow cannabis companies to deduct business expenses and improve access to banking services [1] - Tilray's stock jumped 44% on Friday, reflecting strong market sentiment following the news [2] Group 2: Financial Performance - In fiscal Q1 of 2026, Tilray reported record revenue of $210 million, a 5% year-over-year increase, driven by gains in both domestic and international markets [4] - Sales for adult-use cannabis in Canada rose 12%, while international revenue increased by 10% year-over-year [5] - Tilray achieved a net income of $1.5 million in Q1, a significant improvement from a loss of $34.7 million in the same period last year [5] Group 3: Operational Developments - The beverage segment remained flat as management rationalized its SKUs under Project 420, which has generated $25 million in annual savings [6] - Tilray's craft beer portfolio performed well, with Shock Top emerging as a top-selling brand in the Southeast, where dollar sales rose 49% year-over-year [7] Group 4: Balance Sheet and Financial Health - Tilray strengthened its balance sheet by reducing outstanding debt by $7.7 million, ending with $265 million in cash [8] - The company raised $22.5 million through its at-the-market equity program, improving its net debt to adjusted EBITDA ratio to 0.07x, providing flexibility for future growth investments [8]

Core Insights - Canopy Growth Corporation (CGC) is a leading Canadian cannabis company that cultivates and sells a variety of cannabis, hemp, and cannabinoid-based products through brands like Tweed, DOJA, and 7 Acres [1] Company Overview - Canopy Growth operates as an umbrella organization in the cannabis sector, focusing on a diverse range of products [1] - The company is recognized for its significant presence in the cannabis market, leveraging its brand portfolio to capture consumer interest [1] Investment Focus - The analysis emphasizes a focus on small- to mid-cap companies, which are often overlooked by investors, while also occasionally reviewing large-cap companies to provide a comprehensive view of the equity markets [1]

Group 1: Market Overview - Cannabis stocks experienced a significant surge, with shares jumping as much as 54% across the sector following reports of potential easing of federal marijuana restrictions by President Donald Trump [1] - Curaleaf Holdings (CURLF) has outperformed other cannabis stocks, with a year-to-date increase of 124%, positioning it as a leader in the regulatory-fueled rally [2] Group 2: Company Performance - Curaleaf Holdings has a market capitalization of $2.86 billion, but its stock remains down nearly 70% from all-time highs despite the recent rally [3] - The company reported mixed third-quarter results, with revenue of $320 million, reflecting a 3% year-over-year decrease due to price declines in domestic markets, although international sales rose by 56% year-over-year [5][6] - Curaleaf's adjusted gross margins improved to 50%, up 115 basis points, as cultivation efficiencies helped mitigate pricing pressures [6] Group 3: Product and Operational Insights - Curaleaf offers a variety of cannabis products, including flowers, pre-rolls, and hemp-based products, and engages in the cultivation and sale of hemp-derived THC products [4] - The average flower potency surpassed 30% for the first time in the company's history, attributed to advancements in genetics and growing techniques [7] - The implementation of data-driven analytics tools for merchandising and inventory management is enhancing supply chain efficiency, benefiting from a 2.1 million loyalty member database [7]

Mr. Mavroudis is a professional portfolio manager specializing in institutional and private portfolios. He focuses on risk management, which is accompanied by in-depth financial market analysis (fundamental, macro and technical) to control the risk undertaken by the portfolios. He invests in all financial instruments globally (stocks, bonds, fx, commodities), restructuring investment portfolios based on prevailing conditions and the needs of each client-investor. Mr. Mavroudis has successfully navigated all ...

Green Thumb Industries rallied last week on renewed hope of cannabis rescheduling from the Trump administration. The news appeared in a Washington Post article released on Thursday. US MSOs and Canadian cannabis LPs saw largeWelcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cann ...

Core Insights - Green Thumb Industries experienced a rally due to renewed optimism regarding cannabis rescheduling from the Trump administration, as reported in a Washington Post article [1] Industry Summary - The news has positively impacted US multi-state operators (MSOs) and Canadian cannabis licensed producers (LPs), indicating a potential shift in the regulatory landscape for the cannabis sector [1]

Core Insights - Cannabis stocks experienced a significant surge on December 12, 2025, due to reports of President Trump's plans to ease federal marijuana regulations by reclassifying it to Schedule III from Schedule I, leading to increased investor optimism [1][2] - The potential reclassification could allow cannabis companies to benefit from different tax regulations and encourage further investment, with expectations for the change to materialize early next year [2][4] - The reported policy change is viewed positively by industry experts, as it would facilitate banks in providing services to cannabis-related businesses, with a finalized rule anticipated by summer 2026 [4] Market Performance - Major cannabis ETFs saw substantial gains on December 12, 2025, including Amplify Seymour Cannabis ETF (CNBS) up over 54%, Roundhill Cannabis ETF (WEED) up 55.7%, Advisorshares Pure US Cannabis ETF (MSOS) up 54.3%, Amplify Alternative Harvest ETF (MJ) up 42.8%, Advisorshares Pure Cannabis ETF (YOLO) up 34.5%, and Cambria Cannabis ETF (TOKE) up 20.9% [1][3] - Despite the recent surge, cannabis stocks have faced challenges since the pre-Covid boom, with Tilray (TLRY) shares down approximately 84.4% over the past five years and the MJ ETF declining about 78.9% during the same period [5][6] Industry Outlook - The potential regulatory shift is seen as a step towards normalizing cannabis under federal law, with increasing acceptance and easing regulations in several states [5] - The cannabis industry has shown signs of recovery during Trump's second term, evidenced by a 37% increase in the MJ ETF and a 53.9% surge in the MSOS ETF [6]

Company Overview - Aurora Cannabis Inc. (NASDAQ:ACB) is recognized as one of the top sin stocks to consider for investment in 2026, with notable market growth in Europe and Australia [1] - The company operates in the cannabis industry, producing, distributing, and selling cannabis and cannabis-derived products, targeting both medical and consumer segments [4] Recent Developments - On December 2, Aurora's subsidiary, MedReleaf Australia, entered into a distribution agreement with Leafio, Montu Australia's wholesale arm, aimed at providing training materials for medical professionals and enhancing patient access to medical cannabis products across Australia [2] - Following this, on December 11, Aurora launched a new high-potency cannabis product named Black Jelly in the Polish medicinal market, which contains 27% THC and less than 1% CBD [3] - Black Jelly is produced in Aurora's Canadian facilities that are certified under GACP and EU-GMP standards, and it is now available to Polish prescribers [4] Product Portfolio - Aurora's medical cannabis portfolio includes several brands such as MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed, which will be marketed by Leafio [2] - The introduction of Black Jelly adds to the Cannabis flos Aurora range, which already includes products like Farm Gas and Sourdough [3]

Core Insights - 420 Investor was launched in 2013, coinciding with Colorado's legalization of cannabis for adult use, and has now transitioned to Seeking Alpha for broader coverage of the cannabis sector [1] - The service provides extensive resources for investors, including model portfolios, videos, and written materials focused on cannabis stocks [1] - Alan Brochstein, a pioneer in cannabis investment analysis, has been managing the 420 Investor group and closely follows 20 cannabis stocks, offering investment news and earnings report analyses [1] Company and Industry Overview - The cannabis industry has seen significant interest from investors, particularly with the establishment of platforms like 420 Investor that cater specifically to this market [1] - The transition of 420 Investor to Seeking Alpha indicates a strategic move to enhance visibility and accessibility for investors interested in cannabis stocks [1] - Alan Brochstein's background in financial services and his role in founding New Cannabis Ventures highlight the growing importance of specialized financial analysis in the cannabis sector [1]